TotalMarketCap

Rallybio

RLYBNasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$84.743 M

$15.74 -1.01%

Close of 6 Nov 2026

As of 6 Nov 2026, Rallybio (RLYB) has a market capitalization of $84.7M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$858.0K

#3469 by revenue

Earnings

-$8.98M

Loss-making

Shares outstanding

5,383,937

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #299vTv TherapeuticsVTVT$86.4M
  2. #300Milestone PharmaceuticalsMIST$86.0M
  3. #301RallybioRLYB$84.7M
  4. #302Retension PharmaceuticalsRTSN$83.4M
  5. #303GeneluxGNLX$82.3M

What if Rallybio were worth as much as…

Open the what-if tool →

Gold $28.2T

$5,244,652

Per share 333,205× higher

Bitcoin $1.53T

$283,778.97

Per share 18,029× higher

Apple $5.02T

$931,619.86

Per share 59,188× higher

Or at a round number

$200.0M$500.0M$1.00B$2.00B

Where these numbers come from

Share counts and financials for Rallybio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.